Ann: CEO Half-Year Update, page-2

Another excellent report from Ron - demonstrating excellent fiscal management, recognition and responsiveness to manufacturing lead times and great understanding of the benefits of partnerships and collaborations.

I particularly like the foreshadowing of the almost unlimited potential of the Gen 2 device, as per:

"With our Gen 1 device now under clinical investigation, product development and engineering resources in Sydney, alongside our Brisbane colleagues at the Translation Research Institute, have been freed up to expediate the development of our Gen 2 product. Inhuman testing with the prototype system is slated for later this year with road/air ambulance trials targeted for next year. We are designing and developing this product to be to be truly scalable with ease of use and deployability. It has the potential to revolutionise pre-hospital stroke and traumatic brain injury care worldwide".